NCT05017493

Treatment of Covid-19 With a Herbal Compound, Xagrotin

Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 661 (actual)
• Sponsor: Biomad AS · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

Detailed description

This is an interventional, multi-center, randomized study that has been performed in an outpatient setting (n=361). Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited. Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome. Adverse events were registered.

Conditions

• Covid19

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Xagrotin	A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care

Timeline

• Start date: 2020-07-01
• Primary completion: 2020-12-07
• Completion: 2021-02-08
• First posted: 2021-08-24
• Last updated: 2021-12-02
• Results posted: 2021-12-02

Locations

1 site across 1 country: Iraq